Protagonist Therapeutics announced the presentation of final data from the Phase 2 REVIVE study of rusfertide in polycythemia vera at the 66th Annual American Society of Hematology (ASH) Meeting. The results highlighted durable hematocrit control in patients.
The study demonstrated that 54% of patients experienced more than 2.5 years of durable hematocrit (Hct) control, maintaining levels below 45%. This was accompanied by decreased phlebotomy use and improvements in patient-reported outcomes.
These final Phase 2 results reinforce rusfertide's potential as a significant treatment option for patients with polycythemia vera. The long-term tolerability and sustained efficacy observed in the study provide strong support for its continued development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.